Giuseppe Lanzino

TL;DR: Aneurysm treatment with the Pipeline Embolization Device is associated with the lowest complication rates when used to treat small ICA aneurysms and Procedure-related morbidity and mortality are higher in the treatment of posterior circulation and giant aneurYSms.

TL;DR: It is demonstrated that giant aneurysms represent almost 50 % of delayedAneurysm ruptures in the flow diverter literature, and a substantial proportion of DIPHs occur early following FDS treatment of giant anuerysms.

TL;DR: Patients treated with the PED for large and giant ICA aneurysms had excellent neuroophthalmological outcomes 6 months after the procedure, with deficits improving in most of the patients, very few deficits worsening, and few new deficits developing.

TL;DR: The introduction of flow divert-ers for clinical use is the culmination of a long development period that started 20 years ago and is a classic example of an idea based on theoretical and in vitro studies, confirmed by animal experiments and eventually reaching the clinical arena.

TL;DR: The development of flow diversion devices through in vitro and in vivo studies to clinical practice and summarize recent clinical data are reviewed.